Generation and selection of novel human-neutralizing single chain variable fragments against rabies virus from immunized phage display libraries
Issued Date
2025-03-20
Resource Type
eISSN
24058440
Scopus ID
2-s2.0-86000159097
Journal Title
Heliyon
Volume
11
Issue
6
Rights Holder(s)
SCOPUS
Bibliographic Citation
Heliyon Vol.11 No.6 (2025)
Suggested Citation
Chorpunkul A., Boonyuen U., Limkittikul K., Saengseesom W., Phongphaew W., Putchong I., Yamabhai M., Hajitou A., Benjathummarak S., Lekcharoensuk P., Pitaksajjakul P., Ramasoota P. Generation and selection of novel human-neutralizing single chain variable fragments against rabies virus from immunized phage display libraries. Heliyon Vol.11 No.6 (2025). doi:10.1016/j.heliyon.2025.e42923 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/106699
Title
Generation and selection of novel human-neutralizing single chain variable fragments against rabies virus from immunized phage display libraries
Corresponding Author(s)
Other Contributor(s)
Abstract
Rabies remains a deadly infectious disease in tropical areas caused by rabies virus (RABV). Currently, there are limitations in the production and quality control of polyclonal antibodies for postexposure prophylaxis (PEP) for severe patients. Engineered therapeutic monoclonal antibodies (MAbs) are effective therapies against various infectious agents; therefore, we aimed to develop human MAbs against RABV on a single-chain variable fragment (scFv) platform. Immunized scFv libraries were constructed from human peripheral blood mononuclear cells via the pMOD1 phage display system. Diverse VHVLκ and VHVLλ phage-displayed libraries were successfully produced with 2x107 and 5.4x106 clones, respectively. The high affinity and binding specificity of scFvs targeting the RABV glycoprotein were obtained through biopanning and ELISA. Six unique scFv clones presented diverse complementary determining region (CDR) sequences. Interestingly, HuRABVscFv1 and HuRABVscFv2 exhibited rapid fluorescent foci inhibition test (RFFIT)-neutralizing titers above the 0.5 IU/ml protective level. Finally, in silico molecular docking demonstrated that the CDRs of two neutralizing human clones interact mainly with antigenic sites III (HuRABVscFv1) and II (HuRABVscFv2) on the RABV glycoprotein. These scFvs may be candidates for MAb production against RABV to replace traditional PEP in Thailand.